Lovenox ANDA filings
Two generic firms - Amphastar and Teva - have filed Paragraph IV certifications against Lovenox (enoxaparin), Aventis announces. The certifications challenge the product's 5,389,618 patent, which expires in February 2012, but not its 4,692,435 patent, which expires in December 2004. Aventis is seeking a re-issuance of the '618 patent as part of its patent defense of the low-molecular weight heparin (1"The Pink Sheet" May 5, 2003, p. 10). ANDA filings for the product attracted attention in early April when FDA posted, and then removed, Lovenox from the list of products which have Paragraph IV certifications. Amphastar said that its ANDA was approved for filing April 21...
You may also be interested in...
Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.